Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Acupuncture and Clomiphene Citrate on Live Birth in Anovulatory Women With Polycystic Ovary Syndrome (PCOSAct)

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2013 by Heilongjiang University of Chinese Medicine
Sponsor:
Collaborators:
Yale University
Penn State University
Göteborg University
The University of Hong Kong
Beijing University of Chinese Medicine
Sichuan University
Second Affiliated Hospital,Heilongjiang University of Chinese Medicine
Harbin Medical University
The Daqing Oilfield General Hospital
Daqing Longnan Hospital
Liaoning University of Chinese Medicine Affiliated Hospital
Tianjin University of Traditional Chinese Medicine
Tianjin Tanggu Maternity and Child Care Center
Wenzhou Chinese Medicine Hospital
Integrated Chinese and Western Medicine Hospital of Zhejiang Province
Hangzhou Chinese Medicine Hospital
Shanxi Chinese Medicine Hospital
Henan Chinese Medicine Hospital
Maternal and Child Health Hospital of Xuzhou
Huaian Maternal and Child Health Care Hospital
The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine
Suzhou Chinese Medicine Hospital
Wuhan TongJi Hospital
Hubei Chinese Medicine Hospital
Jiangxi University of Chinese Medicine Affiliated Hospital
First Affiliated Hospital,Hunan University of Chinese Medicine
The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine
Guangdong General Hospital
Guangzhou Liwan Chinese Hospital
Dalian maternity hospital
Information provided by (Responsible Party):
Xiaoke Wu, Heilongjiang University of Chinese Medicine
ClinicalTrials.gov Identifier:
NCT01573858
First received: April 4, 2012
Last updated: February 1, 2013
Last verified: February 2013
  Purpose

The objectives of the present trial are to test the following three hypotheses in anovulatory women with PCOS:

  1. Acupuncture protocol 1 plus CC (Arm A) is more likely to result in live birth than acupuncture protocol 2 combined with CC (Arm B),
  2. Acupuncture protocol 2 plus CC (Arm B) is more likely to result in live birth than acupuncture protocol 1 plus placebo (Arm C),
  3. Acupuncture protocol 1 plus placebo (Arm C) is more likely to result in live birth than acupuncture protocol 2 plus placebo (Arm D).

Condition Intervention
Pregnancy
Polycystic Ovary Syndrome
Infertility
Other: Acupuncture treatment 1
Other: Acupuncture treatment 2
Other: CC
Other: CC placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effect of Acupuncture and Clomiphene Citrate on Live Birth in Anovulatory Women With Polycystic Ovary Syndrome: A Randomized Controlled Trial (PCOSAct)

Resource links provided by NLM:


Further study details as provided by Heilongjiang University of Chinese Medicine:

Primary Outcome Measures:
  • Live birth rate [ Time Frame: Up to 3 years ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Ovulation rate [ Time Frame: Up to 3 years ] [ Designated as safety issue: No ]
  • Ongoing pregnancy rate [ Time Frame: Aprial 2012 to July 2014 (up to 3 years) ] [ Designated as safety issue: Yes ]
    Up to 3 years

  • Multiple pregnancy rate [ Time Frame: Up to 2 years ] [ Designated as safety issue: Yes ]
  • Miscarriage rate [ Time Frame: Up to 2 years ] [ Designated as safety issue: Yes ]
    loss of an intrauterine pregnancy before 20 completed weeks of gestation.

  • Hormonal profile [ Time Frame: Up to 2 years ] [ Designated as safety issue: No ]
    Hormonal profile include: Testosterone(T), Sex hormone-binding globulin (SHBG), Follicle stimulating hormone (FSH),Luteinizing hormone(LH),and Dehydroepiandrosterone sulfate (DHEAS).

  • Metabolic profile [ Time Frame: Up to 2 years ] [ Designated as safety issue: No ]
    Metabolic profile includes: Serum glucose concentration, Insulin concentration, cholesterol, Triglycerides (TG), High density lipoprotein cholesterol (HDL-C) and Low density lipoprotein cholesterol (LDL-C)

  • Side effect profile [ Time Frame: Up to 2 years ] [ Designated as safety issue: Yes ]
    Side effects of CC include hot flashes, mood changes, bloating, formation of ovarian cysts, and pain, extremely rare are pituitary apoplexy and deep venous thrombosis. The major side effects of acupuncture are local skin irritation, discomfort, and vasovagal reactions during the procedure. All above mentioned side effects will be recorded weekly.


Estimated Enrollment: 1000
Study Start Date: April 2012
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Acupuncture treatment 1 plus CC Other: Acupuncture treatment 1
Two sets of acupuncture points will be alternated every second treatment. The first set consists of CV3, CV 6, and ST 29 bilaterally,SP 6 and SP 9 bilaterally. Needles will also be placed in LI bilaterally and GV 20. CV 3, CV 6, ST 29, SP 6, and SP 9 will be connected to and electrical stimulator and stimulated with low-frequency EA of 2Hz, 0.3 ms.
Other: CC
CC 50 mg every day for 5 days (day 3-7 of cycle), for a total of 4 cycles. Non-response will be defined after 4 weeks of CC placebo administration with 3 consecutive weekly negative P4 and hCG levels. Then during the fifth week a higher dose consisting of one more tablet per day (up to 3 tablets per day at third or fourth cycles, if they remain non-responders) will be given 5 days.
Active Comparator: Acupuncture treatment 2 plus CC Other: Acupuncture treatment 2
Needles will be inserted to a depth of <5 mm, one in each shoulder and on in each upper arm at non-acupuncture points. Electrodes will be attached to the needles and the stimulator will be turned on at an intensity of zero (no active current) in order to mimic EA in the acupuncture treatment 1. No manual stimulation of the needles will be performed.
Other: CC
CC 50 mg every day for 5 days (day 3-7 of cycle), for a total of 4 cycles. Non-response will be defined after 4 weeks of CC placebo administration with 3 consecutive weekly negative P4 and hCG levels. Then during the fifth week a higher dose consisting of one more tablet per day (up to 3 tablets per day at third or fourth cycles, if they remain non-responders) will be given 5 days.
Active Comparator: Acupuncture treatment 1 plus CC placebo Other: Acupuncture treatment 1
Two sets of acupuncture points will be alternated every second treatment. The first set consists of CV3, CV 6, and ST 29 bilaterally,SP 6 and SP 9 bilaterally. Needles will also be placed in LI bilaterally and GV 20. CV 3, CV 6, ST 29, SP 6, and SP 9 will be connected to and electrical stimulator and stimulated with low-frequency EA of 2Hz, 0.3 ms.
Other: CC placebo
CC placebo 50 mg every day for 5 days (day 3-7 of cycle), for a total of 4 cycles. Non-response will be defined after 4 weeks of CC Placebo administration with 3 consecutive weekly negative P4 and hCG levels. Then during the fifth week a higher dose consisting of one more tablet per day (up to 3 tablets per day at third or fourth cycles, if they remain non-responders) will be given 5 days.
Active Comparator: Acupucture treatment 2 and CC placebo. Other: Acupuncture treatment 2
Needles will be inserted to a depth of <5 mm, one in each shoulder and on in each upper arm at non-acupuncture points. Electrodes will be attached to the needles and the stimulator will be turned on at an intensity of zero (no active current) in order to mimic EA in the acupuncture treatment 1. No manual stimulation of the needles will be performed.
Other: CC placebo
CC placebo 50 mg every day for 5 days (day 3-7 of cycle), for a total of 4 cycles. Non-response will be defined after 4 weeks of CC Placebo administration with 3 consecutive weekly negative P4 and hCG levels. Then during the fifth week a higher dose consisting of one more tablet per day (up to 3 tablets per day at third or fourth cycles, if they remain non-responders) will be given 5 days.

Detailed Description:

This is a multicenter, randomized, controlled, 2 by 2 factorial clinical trial for Chinese women with PCOS.

Primary outcomes:

- Live birth rate

Secondary outcomes:

  • Ovulation rate
  • Ongoing pregnancy rate
  • Multiple pregnancy rate
  • Miscarriage rate
  • Hormonal profile
  • Metabolic profile
  • Side effect profile
  Eligibility

Ages Eligible for Study:   20 Years to 40 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria
  1. Inclusion Criteria:

    • Age of women between 20 and 40 years.
    • Confirmed diagnosis of PCOS according to the modified Rotterdam criteria and all subjects must have anovulation plus either polycystic ovaries and/or hyperandro-genism.
    • Patency of at least one tube and a normal uterine cavity shown by hysterosalpingogram, HyCosi or diagnostic laparoscopy.
    • Semen analysis:

      1. a. Sperm concentration ≥15×106/ml and b. total motility (a+b+c) ≥40% or forward motility (a+b) ≥32% in the semen analysis of the husband (based on World Health Organization, 2010).
      2. Total motile sperm count ≥9 million [based on WHO (2010) criteria, volume 1.5 ml; conc 15 million; motility 40%. 1.5 x 15 x 0.04=9 million].
  2. Exclusion Criteria:

    • Exclusion of other endocrine disorders

      • Patients with hyperprolactinemia (defined as two prolactin levels at least one week apart 25 ng/mL or greater or as determined by local normative values). The goal of eliminating patients with documented hyperprolactinemia is to decrease the heterogeneity of the PCOS population. These patients may be candidates for ovulation induction with alternate regimens (dopamine agonists). A normal level within the last year or on treatment is adequate for entry.
      • Patients with FSH levels > 15 mIU/mL. A normal level within the last year is adequate for entry.
    • Patients with uncorrected thyroid disease (defined as TSH < 0.2 mIU/mL or > 5.5 mIU/mL). A normal level within the last year is adequate for entry.

      • Patients diagnosed with Type I or Type II diabetes who are poorly controlled (defined as a glycohemoglobin level > 7.0%), or patients receiving antidiabetic medications such as insulin, thiazolidinediones, acarbose, or sulfonylureas likely to confound the effects of study medication; patients currently receiving metformin XR for a diagnosis of Type I or Type II diabetes or for PCOS are also specifically excluded.
      • Patients with suspected Cushing's syndrome.
    • Use of hormonal or other medication including Chinese Herbal prescriptions which may affect the outcome at least in the past 2 months.
    • Pregnancy within the past 6 weeks.
    • Within 6 weeks post-abortion or postpartum.
    • Breastfeeding within the last 6 months.
    • Acupuncture within the last 6 months.
    • Not willing to give written consent to the study.
    • Additional exclusion criteria

      • Patients on oral contraceptives, depot progestins, or hormonal implants (including Implanon). A two month washout period will be required prior to screening for patients on these agents. Longer washouts may be necessary for certain depot contraceptive forms or implants, especially where the implants are still in place. A one-month washout will be required for patients on oral cyclic progestins.
      • Patients with liver disease defined as AST or ALT > 2 times normal or total bilirubin >2.5 mg/dL. Patients with renal disease defined as BUN > 30 mg/dL or serum creatinine> 1.4 mg/dL.
      • Patients with significant anemia (Hemoglobin < 10 g/dL).
      • Patients with a history of deep venous thrombosis, pulmonary embolus, or cerebrovascular accident.
      • Patients with known heart disease that is likely to be exacerbated by pregnancy.
      • Patients with a history of, or suspected cervical carcinoma, endometrial carcinoma, or breast carcinoma. A normal Pap smear result will be required for women 21 and over.
      • Patients with a current history of alcohol abuse. Alcohol abuse is defined as > 14 drinks/week or binge drinking.
      • Patients enrolled simultaneously into other investigative studies that require medications, proscribe the study medications, limit intercourse, or otherwise prevent compliance with the protocol.
      • Patients who anticipate taking longer than a one month break during the protocol should not be enrolled.
      • Patients taking other medications known to affect reproductive function or metabolism. These medications include oral contraceptives, GnRH agonists and antagonists, antiandrogens, gonadotropins, anti-obesity drugs, Chinese herbal formula, anti-diabetic drugs such as metformin and thiazolidinediones, somatostatin, diazoxide, ACE inhibitors, and calcium channel blockers. The washout period on all these medications will be two months.
      • Patients with a suspected adrenal or ovarian tumor secreting androgens.
      • Couples with previous sterilization procedures (vasectomy, tubal ligation) which have been reversed. The prior procedure may affect study outcomes, and patients with both a reversed sterilization procedure and PCOS are rare enough that exclusion should not adversely affect recruitment.
      • Subjects who have undergone a bariatric surgery procedure in the recent past (< 12 months) and are in a period of acute weight loss or have been advised against pregnancy by their bariatric surgeon.
      • Patients with untreated poorly controlled hypertension defined as a systolic blood pressure 160 mm Hg or a diastolic 100 mm Hg obtained on two measures obtained at least 60 minutes apart.
      • Patients with known congenital adrenal hyperplasia.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01573858

Contacts
Contact: Yan Li, M.D., Ph.D. 86-451-82118464 PCOSACT@gmail.com
Contact: Hongying Kunag, M.D., Ph.D. 86-451-82118464 PCOSACT@gmail.com

  Show 25 Study Locations
Sponsors and Collaborators
Heilongjiang University of Chinese Medicine
Yale University
Penn State University
Göteborg University
The University of Hong Kong
Beijing University of Chinese Medicine
Sichuan University
Second Affiliated Hospital,Heilongjiang University of Chinese Medicine
Harbin Medical University
The Daqing Oilfield General Hospital
Daqing Longnan Hospital
Liaoning University of Chinese Medicine Affiliated Hospital
Tianjin University of Traditional Chinese Medicine
Tianjin Tanggu Maternity and Child Care Center
Wenzhou Chinese Medicine Hospital
Integrated Chinese and Western Medicine Hospital of Zhejiang Province
Hangzhou Chinese Medicine Hospital
Shanxi Chinese Medicine Hospital
Henan Chinese Medicine Hospital
Maternal and Child Health Hospital of Xuzhou
Huaian Maternal and Child Health Care Hospital
The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine
Suzhou Chinese Medicine Hospital
Wuhan TongJi Hospital
Hubei Chinese Medicine Hospital
Jiangxi University of Chinese Medicine Affiliated Hospital
First Affiliated Hospital,Hunan University of Chinese Medicine
The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine
Guangdong General Hospital
Guangzhou Liwan Chinese Hospital
Dalian maternity hospital
Investigators
Principal Investigator: Xiaoke Wu, M.D., Ph.D. First Affiliated Hospital of Heilongjiang Chinese Medicine University
Principal Investigator: Lihui Hou, M.D. First Affiliated Hospital of Heilongjiang Chinese Medicine University
Study Chair: Richard Legro, MD Steering Committee, Pennsylvania State University College of Medicine
Study Chair: Heping Zhang, PHD Data and Quality Control, Yale University
  More Information

No publications provided

Responsible Party: Xiaoke Wu, Professor and Department Chairman of Obstetrics and Gynecology, Heilongjiang University of Chinese Medicine
ClinicalTrials.gov Identifier: NCT01573858     History of Changes
Other Study ID Numbers: PCOSAct
Study First Received: April 4, 2012
Last Updated: February 1, 2013
Health Authority: China: Ministry of Health

Keywords provided by Heilongjiang University of Chinese Medicine:
Infertility
Polycystic Ovary Syndrome
Clomiphene citrate
Acupuncture

Additional relevant MeSH terms:
Polycystic Ovary Syndrome
Syndrome
Infertility
Adnexal Diseases
Cysts
Disease
Endocrine System Diseases
Genital Diseases, Female
Genital Diseases, Male
Gonadal Disorders
Neoplasms
Ovarian Cysts
Ovarian Diseases
Pathologic Processes
Clomiphene
Enclomiphene
Zuclomiphene
Estrogen Antagonists
Estrogen Receptor Modulators
Fertility Agents
Fertility Agents, Female
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Selective Estrogen Receptor Modulators
Therapeutic Uses

ClinicalTrials.gov processed this record on November 23, 2014